Free Trial

Celularity (CELU) Competitors

Celularity logo
$0.61 -0.02 (-2.71%)
As of 02:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CELU vs. HURA, KZIA, BDTX, DTSQ, and OKUR

Should you buy Celularity stock or one of its competitors? Celularity's main competitors and comparable companies include TuHURA Biosciences (HURA), Novogen (KZIA), Black Diamond Therapeutics (BDTX), DT Cloud Star Acquisition (DTSQ), and OnKure Therapeutics (OKUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celularity compare to TuHURA Biosciences?

TuHURA Biosciences (NASDAQ:HURA) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

TuHURA Biosciences currently has a consensus price target of $9.50, suggesting a potential upside of 583.45%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe TuHURA Biosciences is more favorable than Celularity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Celularity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by insiders. Comparatively, 52.9% of Celularity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, TuHURA Biosciences had 3 more articles in the media than Celularity. MarketBeat recorded 4 mentions for TuHURA Biosciences and 1 mentions for Celularity. TuHURA Biosciences' average media sentiment score of 1.21 beat Celularity's score of 0.89 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
TuHURA Biosciences Positive
Celularity Positive

TuHURA Biosciences has a net margin of 0.00% compared to Celularity's net margin of -246.65%. Celularity's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TuHURA BiosciencesN/A -145.33% -101.11%
Celularity -246.65%N/A -48.20%

TuHURA Biosciences has a beta of -0.23, indicating that its stock price is 123% less volatile than the broader market. Comparatively, Celularity has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

TuHURA Biosciences has higher earnings, but lower revenue than Celularity. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TuHURA BiosciencesN/AN/A-$30.05M-$0.54N/A
Celularity$26.55M0.77-$91.72M-$1.69N/A

Summary

TuHURA Biosciences beats Celularity on 8 of the 15 factors compared between the two stocks.

How does Celularity compare to Novogen?

Novogen (NASDAQ:KZIA) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Novogen has a net margin of 0.00% compared to Celularity's net margin of -246.65%.

Company Net Margins Return on Equity Return on Assets
NovogenN/A N/A N/A
Celularity -246.65%N/A -48.20%

Novogen has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, Celularity has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

30.9% of Novogen shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 52.9% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Novogen has higher earnings, but lower revenue than Celularity.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novogen$1.23M69.81-$13.41MN/AN/A
Celularity$26.55M0.77-$91.72M-$1.69N/A

In the previous week, Novogen had 2 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Novogen and 1 mentions for Celularity. Celularity's average media sentiment score of 0.89 beat Novogen's score of 0.42 indicating that Celularity is being referred to more favorably in the news media.

Company Overall Sentiment
Novogen Neutral
Celularity Positive

Novogen presently has a consensus price target of $29.50, indicating a potential upside of 345.62%. Given Novogen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Novogen is more favorable than Celularity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novogen
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
Celularity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Novogen beats Celularity on 10 of the 13 factors compared between the two stocks.

How does Celularity compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 52.9% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Black Diamond Therapeutics has higher earnings, but lower revenue than Celularity. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Black Diamond TherapeuticsN/AN/A$22.37M-$0.77N/A
Celularity$26.55M0.77-$91.72M-$1.69N/A

In the previous week, Black Diamond Therapeutics had 7 more articles in the media than Celularity. MarketBeat recorded 8 mentions for Black Diamond Therapeutics and 1 mentions for Celularity. Celularity's average media sentiment score of 0.89 beat Black Diamond Therapeutics' score of 0.74 indicating that Celularity is being referred to more favorably in the news media.

Company Overall Sentiment
Black Diamond Therapeutics Positive
Celularity Positive

Black Diamond Therapeutics has a beta of 3.48, indicating that its stock price is 248% more volatile than the broader market. Comparatively, Celularity has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Black Diamond Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -246.65%. Celularity's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Black Diamond TherapeuticsN/A -36.66% -28.44%
Celularity -246.65%N/A -48.20%

Black Diamond Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 648.30%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Black Diamond Therapeutics is more favorable than Celularity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Black Diamond Therapeutics
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60
Celularity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Black Diamond Therapeutics beats Celularity on 10 of the 15 factors compared between the two stocks.

How does Celularity compare to DT Cloud Star Acquisition?

DT Cloud Star Acquisition (NASDAQ:DTSQ) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

19.0% of Celularity shares are owned by institutional investors. 52.9% of DT Cloud Star Acquisition shares are owned by company insiders. Comparatively, 52.9% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, DT Cloud Star Acquisition had 1 more articles in the media than Celularity. MarketBeat recorded 2 mentions for DT Cloud Star Acquisition and 1 mentions for Celularity. DT Cloud Star Acquisition's average media sentiment score of 0.91 beat Celularity's score of 0.89 indicating that DT Cloud Star Acquisition is being referred to more favorably in the media.

Company Overall Sentiment
DT Cloud Star Acquisition Positive
Celularity Positive

DT Cloud Star Acquisition has higher earnings, but lower revenue than Celularity.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DT Cloud Star AcquisitionN/AN/AN/AN/AN/A
Celularity$26.55M0.77-$91.72M-$1.69N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DT Cloud Star Acquisition
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Celularity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

DT Cloud Star Acquisition has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, Celularity has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

DT Cloud Star Acquisition has a net margin of 0.00% compared to Celularity's net margin of -246.65%.

Company Net Margins Return on Equity Return on Assets
DT Cloud Star AcquisitionN/A N/A N/A
Celularity -246.65%N/A -48.20%

Summary

DT Cloud Star Acquisition beats Celularity on 6 of the 9 factors compared between the two stocks.

How does Celularity compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

OnKure Therapeutics has a net margin of 0.00% compared to Celularity's net margin of -246.65%. Celularity's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
OnKure TherapeuticsN/A -43.38% -40.74%
Celularity -246.65%N/A -48.20%

OnKure Therapeutics currently has a consensus price target of $17.50, indicating a potential upside of 565.40%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe OnKure Therapeutics is more favorable than Celularity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OnKure Therapeutics
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Celularity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

OnKure Therapeutics has higher earnings, but lower revenue than Celularity. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OnKure TherapeuticsN/AN/A-$59.52M-$2.77N/A
Celularity$26.55M0.77-$91.72M-$1.69N/A

In the previous week, OnKure Therapeutics and OnKure Therapeutics both had 1 articles in the media. OnKure Therapeutics' average media sentiment score of 1.79 beat Celularity's score of 0.89 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
OnKure Therapeutics Very Positive
Celularity Positive

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by insiders. Comparatively, 52.9% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

OnKure Therapeutics has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Celularity has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

Summary

OnKure Therapeutics beats Celularity on 8 of the 14 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CELU vs. The Competition

MetricCelularityBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$19.80M$4.09B$7.86B$11.79B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-0.3624.3834.4130.16
Price / Sales1.0715.078.095.36
Price / CashN/A21.8921.0222.32
Price / Book-0.464.374.783.86
Net Income-$91.72M-$24.19M$3.52B$391.27M
7 Day Performance-19.31%-6.84%-4.98%-4.24%
1 Month Performance-50.96%-4.52%-3.20%-5.57%
1 Year Performance-60.45%-4.21%-0.27%-7.50%

Celularity Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CELU
Celularity
0.3659 of 5 stars
$0.61
-2.7%
N/A-59.3%$19.80M$18.67MN/A115
HURA
TuHURA Biosciences
2.1026 of 5 stars
$1.66
-3.8%
$9.00
+443.8%
-32.2%$105.47MN/AN/A22
KZIA
Novogen
3.8554 of 5 stars
$8.08
+0.7%
$29.50
+265.1%
+5.6%$104.80M$1.23MN/A6
BDTX
Black Diamond Therapeutics
2.7132 of 5 stars
$1.81
+3.4%
$11.00
+507.7%
-63.3%$103.98M$70MN/A21
DTSQ
DT Cloud Star Acquisition
1.8598 of 5 stars
$11.56
+0.0%
N/A+7.0%$102.85MN/AN/A3

Related Companies and Tools


This page (NASDAQ:CELU) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners